Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

REGENERON PHARMACEUTICALS

(REGN)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Regeneron Pharmaceuticals : FDA Accepts Regeneron's 'Regen-Cov" For Priority Review for Treatment, Prophylaxis of COVID-19; Shares Rise

10/14/2021 | 01:47pm EST


ę MT Newswires 2021
All news about REGENERON PHARMACEUTICALS
11/30Officials offer vaccine reassurance; WHO advises against travel bans
RE
11/30US Stocks Slump as Omicron Variant, Fed Chief's Comment on Faster Asset Purchase Taperi..
MT
11/30CLOSE UPDATE : US Stocks See Sharp Decline as Omicron Variant, Fed Chief Comment on Faster..
MT
11/30Yen, Swiss franc rally on global outlook risks after hawkish Powell
RE
11/30ANALYSIS : As Omicron plays havoc with markets, shares of vaccine makers surge
RE
11/30Wall St sinks as taper acceleration worries pile onto virus angst
RE
11/30Pharmaceutical Names to See Increased Volatility into Year End Amid Omicron Updates, Op..
MT
11/30Equities Drop Midday as Moderna CEO Questions COVID-19 Vaccines' Efficacy Against Omicr..
MT
11/30MIDDAY REPORT : US Stocks Drop as Moderna CEO Questions COVID-19 Vaccines' Efficacy Agains..
MT
11/30US Stocks Drop as Moderna CEO Warns on Efficacy of COVID-19 Vaccines Against Omicron; O..
MT
More news
Analyst Recommendations on REGENERON PHARMACEUTICALS
More recommendations
Financials (USD)
Sales 2021 15 430 M - -
Net income 2021 7 903 M - -
Net cash 2021 5 814 M - -
P/E ratio 2021 9,01x
Yield 2021 -
Capitalization 66 553 M 66 553 M -
EV / Sales 2021 3,94x
EV / Sales 2022 4,41x
Nbr of Employees 9 766
Free-Float 81,9%
Chart REGENERON PHARMACEUTICALS
Duration : Period :
Regeneron Pharmaceuticals Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends REGENERON PHARMACEUTICALS
Short TermMid-TermLong Term
TrendsBullishNeutralBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 24
Last Close Price 630,59 $
Average target price 697,52 $
Spread / Average Target 10,6%
EPS Revisions
Managers and Directors
Leonard S. Schleifer Co-President, Chief Executive Officer & Director
George Damis Yancopoulos Co-President, Director & Chief Scientific Officer
Robert E. Landry Chief Financial Officer & Executive VP-Finance
P. Roy Vagelos Chairman
Neil Stahl Executive VP-Research & Development
Sector and Competitors
1st jan.Capi. (M$)
REGENERON PHARMACEUTICALS31.76%66 553
GILEAD SCIENCES, INC.18.31%86 465
BIONTECH SE331.48%84 953
WUXI APPTEC CO., LTD.30.33%66 734
VERTEX PHARMACEUTICALS-20.90%47 530
BEIGENE, LTD.34.50%32 613